Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance

Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB · Cell Metabolism

Null, including on the mechanism. Plasma resveratrol rose, but body composition, resting metabolic rate, lipids and inflammatory markers were unchanged, a two-stage hyperinsulinaemic-euglycaemic clamp with labelled tracers showed no gain in liver, muscle or adipose insulin sensitivity, and the putative molecular targets — AMPK, SIRT1, NAMPT, PPARGC1A — were unaffected in muscle and fat biopsies.

Population

Non-obese postmenopausal women with normal glucose tolerance

Intervention

Resveratrol 75 mg/day for 12 weeks

Comparator

Placebo (one of three randomised arms; a calorie-restriction arm of 15 was randomised alongside but is not reported here)

Limitations

A healthy population with little room to improve, and a low dose. The trial randomised a calorie-restriction arm as well, so the mimetic comparison was available, and this paper does not report it. Part-funded by the ingredient manufacturer, whose product and analytical laboratory the trial used.